News
ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...
AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in chronic lymphocytic leukaemia (CLL) that it says show a safety advantage over Imb
